The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
The European Commission has proposed new rules aimed at strengthening the security of supply and availability of critical ...
Pharmaceutical Technology on MSN1d
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejectionEurope’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
A false claim is circulating online that the European Medicines Agency (EMA) has acknowledged that mRNA vaccines have not been formally approved and that millions have therefore been vaccinated ...
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...
The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...
Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...
of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of a label extension for IXCHIQ ®, Valneva’s single-dose vaccine for the prevention of disease caused ...
Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback